



LAMINAR
PHARMA



FACT SHEET



March 2021

Overview

Laminar Pharma is a **Spanish biopharmaceutical company** committed to **translational health research**. We develop oncology drugs and other “first in class” products, using our patented **Membrane Lipid Therapy (MLT)** technology.

Since 2006, we have been investigating **lipid alterations** that happen in the cell membrane, studying their relationship with various pathological processes and developing **pioneering therapeutic molecules** to improve the quality of life of people who suffer serious diseases.

We control every step of the process, with constant investment in R&D and high-quality standards. We license and supply patents to large pharmaceutical companies worldwide, under a B2B exploitation model.



Management

Pablo Escribá	President and Founder
Victoria Lladó	General Manager USA
Paula Fernández	CSO
Armando Cuesta	Medical Director
Antonio J. González	CFO
David Roberto	Financial Controller
Catalina Ana Roselló	Head of CMC
Adrian McNicholl	CCO
María Sola Gil	Strategic Drug Development Director
Richard J. Taylor	Head of Regulatory & Medical Affairs
Manuel Illescás	Intellectual Property
José Javier Muruzábal	Product Development
Irene Tato	Director of Communication

Pipeline

We are developing molecules grouped into three therapeutic areas:

- Oncology (Brain Tumor and Pediatric Cancer)
- Neurodegenerative Diseases
- Infectious diseases



LAMINAR PHARMACEUTICAL'S PIPELINE

COMPOUND	R&D	Preclinical	Phase I	Phase II	Phase III	Market
LAM561 Glioma Adults	→					2022/2023
LAM561 Glioma Pediatric	→					2023/2024
* LAM182 Oncology	→					2024/2025
* LAM181 Neuropathic Pain	→					2024/2025
LAM226 Down's Syndrome	→					2027/2028
LP109C2-5/11 Cancer	→					2032/2033

* Out-licensed under a B2B exploitation model

Highlights

In 2006, the **first spin-off company of the University of the Balearic Islands** was established in Mallorca as a technology-based business project.

Laminar's initial purpose was to develop and produce innovative synthetic unsaturated fatty acid therapies for some **rare, pediatric and geriatric diseases**.

Aimed at **groups with unmet clinical needs** in oncological and neurodegenerative diseases, as well as some metabolic disorders.

Laminar Pharma is recognized for creating an **innovative scientific platform called Membrane Lipid Therapy (MLT)**.

The company is a pioneer in its therapeutic approach, based on the **synthetic design of lipid molecules** and compounds derived from oleic acid.

Today the company **patents** for synthetic fatty acids are divided into seven families, some of which have been **licensed for development** to other biotechnology companies in Spain.

In 2020, Laminar is one of the 169 national organizations that are **part of the Spanish Association of Biotechnology Companies (ASEBIO)**, specifically within the Health Biotechnology group. We are responsible for 8% of new drug developments in the Spanish pipeline of red biotechnology from the ASEBIO website (see <http://pipelines.asebio.com/red/>).

Contact Information

Carretera Valldemossa km 7,4 PARC BIT
Edificio Naorte, Bloque A, 1ª planta. Puerta 3
07121 Baleares (SPAIN)
+34 971 43 98 86

Business Development
bd@laminarpharma.com

A decorative graphic at the bottom of the page depicts a cross-section of a lipid bilayer, showing two layers of phospholipids with their hydrophilic heads facing outwards and hydrophobic tails facing inwards.

FACT SHEET
March 2021



www.laminarpharma.com



[@LaminarPharma](https://twitter.com/LaminarPharma)